Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron with PLD and Adebrelimab in Relapsed Ovarian Cancer
NCT06791460Phase 3Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Mar 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mirabegron in ovarian cancer (2 arms), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
mirabegron
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06791460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791460.